Intervention: Doxycycline
Trial phase: Phase 2
ATC code: A01AB22 | J01AA02 | J01AA20
SMILES: [H][C@@]12C(=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]3([H])[C@H]1O)C(=O)c1c(O)cccc1[C@@H]2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Patients will receive oral doxycycline and trough serum concentrations for pharmacokinetic studies will be obtained.

Doxycycline: Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
Eligibility criteria:
Inclusion Criteria:

Histologically or cytologically confirmed pancreatic adenocarcinoma which may be acquired using a fine needle aspiration.
Not received any prior therapy.
Established resectable pancreatic cancer based on radiographic imaging.
Patients who will receive neoadjuvant therapy (chemoradiation) are eligible.
Age ≥18 years.
Eastern Cooperative Oncology Group (ECOG) performance status ≤2 (Karnofsky ≥60%).
Have no active or chronic infection with HIV, Hepatitis B or Hepatitis C
Life expectancy of greater than six months.
Ability to understand and the willingness to sign a written informed consent document.

Normal organ and marrow function as defined below:

leukocytes ≥3,000/microliter (mcL)
absolute neutrophil count ≥1,500/mcL
platelets ≥100,000/mcL
total bilirubin < 2 mg/dL or has demonstrated progressive decline within two weeks of biliary decompression to allow for appropriate gemcitabine dose modification.
Aspartate Aminotransferase (AST)[Serum Glutamic Oxaloacetic Transaminase (SGOT] )/ Alanine Aminotransferase (ALT) [Serum Glutamic Pyruvic Transaminase(SGPT)] ≤3 × institutional upper limit of normal
Creatinine clearance ≥60 mL/min/1.73 m^2

Exclusion Criteria:

Patients with more clinically advanced pancreatic cancer (borderline resectable, locally advanced, or metastatic).
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded from this study because the effects of metakaryocidal agents have the potential for teratogenic or abortifacient effects.
Previous history of other malignancy (other than cured basal or squamous cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within two years of study enrollment.
Active or chronic HIV, hepatitis B or hepatitis C.
Patients who are receiving other investigational drugs or enrolled in other clinical trials.
Inability to undergo scheduled blood acquisition per protocol.
Drug specific exclusion including history of allergic reactions to tetracyclines.
Prior treatment with doxycycline within a seven day washout period prior to initiating treatment with alternate antimetakaryocidal medication.